Palliative care - secretions
Exam Tips
- In OSCEs, prioritise communication: explain to relatives that the sound is common at end of life and often not a sign of patient distress.
- First-line practical step is repositioning (side-lying, head-up) before drug escalation.
- Know UK palliative SC dosing: glycopyrronium, hyoscine butylbromide, and hyoscine hydrobromide bolus plus 24-hour CSCI ranges.
- Hyoscine hydrobromide is centrally acting (crosses BBB): higher risk of confusion/delirium/sedation than glycopyrronium or hyoscine butylbromide.
- Reassess efficacy and harms within 4-12 hours and stop/switch if ineffective after ~12 hours or if side effects are problematic.
- For visual memory, review a diagram of hypopharyngeal secretion pooling and postural drainage in palliative medicine texts (e. g, Twycross palliative care chapters).
Definition
Noisy respiratory tract secretions in palliative care are audible gurgling, rattling, or bubbling breath sounds caused by pooled saliva and airway mucus in a person who is in the last days of life. It is a terminal-phase sign (often called a "death rattle") that is usually more distressing to relatives and staff than to the semi-conscious or unconscious patient.
Pathophysiology
Secretions from salivary glands (most commonly) and bronchial mucosa accumulate in the hypopharynx and larger airways when clearance fails. Clearance drops because swallowing and cough weaken with reduced consciousness, neuromuscular exhaustion, sedative/opioid exposure, and bedbound supine positioning; dehydration can make mucus more tenacious, and ciliary dysfunction (for example smoking-related) further impairs transport. Secretion burden may also increase due to chest infection, pulmonary oedema, bronchorrhoea (classically bronchoalveolar-pattern malignancy), gastro-oesophageal reflux, or aspiration of oropharyngeal/gastric contents. Turbulent airflow through pooled fluid produces the characteristic inspiratory and expiratory noise without necessarily indicating patient dyspnoea.
Risk Factors
- Actively dying phase with declining consciousness
- Weak/absent swallow and cough reflexes
- Sedative, hypnotic, or opioid use reducing airway clearance
- Dehydration causing thick, sticky mucus
- Supine or semi-recumbent positioning
- Chest infection with purulent sputum
- Pulmonary oedema
- Aspiration risk (older age, impaired gag reflex, structural upper GI/airway disease)
- Smoking-related impaired mucociliary function
- Bronchorrhoea from pulmonary malignancy (rare)
Clinical Features
Symptoms
- Often no reported distress from the patient if drowsy/unconscious
- Family/carer distress due to loud "rattle"
- Possible choking/cough episodes if aspiration is ongoing
- Associated symptoms from cause (e. g, fever/purulent sputum in infection, orthopnoea in pulmonary oedema)
Signs
- Persistent gurgling/rattling/bubbling airway noise during inspiration and expiration
- Terminal-phase features: bedbound state, minimal oral intake, drowsiness/coma, altered breathing pattern, peripheral coolness/cyanosis
- Pooling of secretions in upper airway/hypopharynx
- May coexist with signs of delirium or sedation (especially with centrally acting antimuscarinics)
Investigations
Management
Lifestyle Modifications
- Reposition laterally with head/upper body elevated to aid postural drainage
- Give clear, proactive explanation to family that noise is common near end of life and is often not uncomfortable for the patient
- Individualise goals of care and avoid burdensome interventions in the last days unless they improve comfort
- Consider gentle oropharyngeal suction only if secretions are accessible and causing clear distress
Pharmacological Treatment
Antimuscarinics (off-label for terminal secretions)
- Glycopyrronium bromide 200-400 micrograms SC stat, then 600-1200 micrograms/24 h by continuous SC infusion (CSCI)
- Hyoscine butylbromide 20 mg SC stat, then 60-180 mg/24 h by CSCI
- Hyoscine hydrobromide 200-400 micrograms SC stat, then 1200-2400 micrograms/24 h by CSCI
Use when positioning/conservative measures are insufficient and distress persists. Reassess response after initial dose (about 20-60 minutes depending on agent) and monitor at least 4- to 12-hourly; allow up to 12 hours for full effect before switching/stopping unless adverse effects are unacceptable. Common adverse effects: dry mouth, urinary retention, constipation, blurred vision, drowsiness, agitation. Hyoscine hydrobromide crosses the blood-brain barrier and is more likely to cause confusion, delirium, and sedation (greater caution in older/frail adults). Use caution/avoid in clinically significant urinary retention, severe constipation/ileus, narrow-angle glaucoma risk, tachyarrhythmias, and myasthenia gravis; review interactions with other anticholinergic drugs.
Antibiotics for distressing infected secretions (selected cases only)
- Broad-spectrum antibiotic as a single dose in an imminently dying patient when profuse purulent sputum from chest infection is clearly driving distress; consider second dose only if clear early benefit and after specialist advice
Antibiotics usually do not change overall dying trajectory; prescribe only when likely to improve comfort. Discuss rationale sensitively with family/carers to align treatment with end-of-life goals.
Complications
- Family/carer psychological distress and fear of patient suffering
- Antimuscarinic adverse effects (delirium, agitation, excessive sedation, urinary retention, severe dry mouth)
- Potential aspiration events and recurrent aspiration pneumonia
- Unnecessary burdensome interventions if prognosis and goals are not clarified
Prognosis
Noisy respiratory secretions are a strong marker of impending death in the terminal phase. Reported prevalence in dying patients is broad (about 23-92%), and onset is commonly within the last 17-57 hours of life; in one palliative cohort, most affected patients died within 48 hours.
Sources & References
✅NICE Guidelines(1)
- Palliative care - secretions[overview]